Integrated Immune Engineering for Poor Prognosis Cancers

Search results

• Active

  Administrative Core

  Odde, D. J.

  National Cancer Institute

  8/1/23 → 7/31/24

  Project: Research project

  • Bioengineering 100%
  • Immunotherapy 67%
  • Genome 51%
  • Neoplasms 49%
  • Education 48%

• Project 1

  Odde, D. J.

  National Cancer Institute

  8/1/23 → 7/31/24

  Project: Research project

  • Tumors 100%
  • T-cells 52%
  • Cells 43%
  • Brain 29%
  • Peptides 23%
• Finished

  Project 1

  Odde, D. J. & Odde, D. J.

  National Cancer Institute

  7/1/21 → 7/31/23

  Project: Research project

  • Tumors 100%
  • T-cells 52%
  • Cells 43%
  • Brain 29%
  • Peptides 23%

• Administrative Core

  Odde, D. J. & Odde, D. J.

  National Cancer Institute

  7/1/21 → 7/31/23

  Project: Research project

  • Bioengineering 100%
  • Genome 69%
  • Immunotherapy 67%
  • Neoplasms 65%
  • Education 48%

• Project 2

  Provenzano, P. & Provenzano, P. P.

  National Cancer Institute

  7/1/21 → 7/31/23

  Project: Research project

  • T-Lymphocytes 100%
  • Neoplasms 55%
  • Cell Engineering 50%
  • Cell- and Tissue-Based Therapy 26%
  • Gene Editing 23%

• Project 3

  Moriarity, B. S. & Moriarity, B. B. S.

  National Cancer Institute

  7/1/21 → 7/31/23

  Project: Research project

  • T-Lymphocytes 100%
  • Gene Editing 99%
  • Tumor Microenvironment 65%
  • Chimeric Antigen Receptors 48%
  • Technology 41%